Cytokinetics drops as $650 million common-stock offering sparks dilution fears
CYTK•Cytokinetics shares are sliding after the company launched a $650 million underwritten common-stock offering announced May 5, 2026, raising near-term dilution concerns. The move follows its May 5 first-quarter update showing a $206.0 million net loss and higher SG&A tied to the MYQORZO launch.
1. What’s moving the stock
Cytokinetics (CYTK) is down today as investors digest a new equity financing. On May 5, 2026, the company announced a proposed underwritten public offering of about $650 million of common stock, including a 30-day option for underwriters to buy up to an additional 15% of shares. The prospect of a large share issuance is pressuring the stock due to dilution and deal-pricing uncertainty. (globenewswire.com)
